Navigation Links
ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
Date:1/22/2009

ng its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.

Any statements contained in this press release referring to future events or other non-historical matters are forward-looking statements. Without limiting the foregoing, but by way of example, statements contained in this press release related to the anticipated design of future ecabet sodium studies, the results of future or ongoing studies with lower strength Xibrom, ISTA's intention to select one or more products to advance to Phase III in 2010, ISTA's belief that ecabet sodium not only improves the quality of tears but also increases the quantity of tears, ISTA's belief that conducting two successful Phase III environmental clinical trials for improvement in signs and two successful Phase III controlled chamber clinical trials for the improvement of symptoms should lead to marketing approval of ecabet sodium and ISTA's expectation of becoming the leading niche ophthalmic pharmaceutical company are forward-looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. These forward-looking statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others, delays and uncertainties related to the FDA or other regulatory agency approval or actions; the uncertain nature of clinical research and uncertainties and risks regarding market acceptance of and demand for ISTA's approved products; and such other risks and uncertainties as detailed from time to time in ISTA's public filings with the U.S. Securities and E
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. ISTA Pharmaceuticals New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
4. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
5. Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
6. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
7. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
8. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
9. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Mich., Dec. 16 GlaxoSmithKline plc [GSK] ... today announced an exclusive licensing agreement in the ... use of NB-001, a novel, patented compound representing ... sores. Developed by NanoBio, NB-001 provides significant antimicrobial ... herpes labialis . ,, Cold sores ...
(Date:12/16/2009)... CORALVILLE, Iowa, Dec. 16 Vivakor, ... a Business Development agreement with Baker Consulting ... affiliate group, Kyouko Group, Inc. out of ... retained by Vivakor to assist with business ... its recently reported acquisition strategy. Specifically, Baker ...
(Date:12/16/2009)... Frost & Sullivan,s ... to speaking at the 2010 International Consumer ... January 9, 2010 in Las Vegas. ... of consumer-based digital health and wellness devices, ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, Bujnoch focuses on patient ...
Breaking Medicine Technology:GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment 2Vivakor Signs Business Development Agreement With Baker Consulting 2Frost & Sullivan to Speak at 2010 International Consumer Electronics Digital Health Summit 2For Organ Donation Intent and Reality Dont Align 56981 1For Organ Donation Intent and Reality Dont Align 56981 2For Organ Donation Intent and Reality Dont Align 56981 3H1N1 frenzy may allow regular flu to be more deadly than ever 56980 1H1N1 frenzy may allow regular flu to be more deadly than ever 56980 2Early spring time for Edinburgh 3F Study predicts effect of global warming on spring flowers 9896 1Early spring time for Edinburgh 3F Study predicts effect of global warming on spring flowers 9896 2
... HOUSTON, LONDON and RESEARCH TRIANGLE PARK, N.C., Nov. ... (NYSE: GSK ),announced today that the U.S. ... approvable letter for the new drug application for ... of adults with major,depressive disorder. The FDA ...
... Nov. 2 GeoVax Labs, Inc. (OTC,Bulletin Board: ... safety and immunogenicity data from its full-dose HIV/AIDS,vaccine ... This full-dose trial is the second in a ... test the safety and immunogenicity of the GeoVax,HIV/AIDS ...
Other Medicine Technology:Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder 2Excellent Results Received from GeoVax's Full-Dose HIV/AIDS Vaccine Trial 2Excellent Results Received from GeoVax's Full-Dose HIV/AIDS Vaccine Trial 3Excellent Results Received from GeoVax's Full-Dose HIV/AIDS Vaccine Trial 4
(Date:12/16/2009)... Balance, Inc. (Nasdaq: SMBL ) announced today that ... repurchase program of up to $25 million, to begin ... we have in the prospects of our Company and ... of our shareholders, while at the same time making ... Inc. Chairman and Chief Executive Officer. ,, Any purchases ...
(Date:12/16/2009)... CHASE, Md., Dec. 16 New Enterprise ... firm, today announced that one of its portfolio ... agreement to be acquired by Ethicon, Inc., a ... for approximately $785 million (net of estimated cash ... technology company dedicated to designing, developing and commercializing ...
(Date:12/16/2009)... benefit from breakthroughs, experts say, , , WEDNESDAY, Dec. 16 ... used for research come mostly from white donors, a ... non-whites will benefit less from any medical breakthroughs that ... , Blacks could be especially affected. In fact, none ... showed any traces of recent African ancestry, the team ...
(Date:12/16/2009)... Losing has never felt so good for "The Biggest ... lifestyle means continuing to make smart choices everyday to ... one healthy choice that is an important part of ... take. Every glass of milk has nine essential nutrients ... normal blood pressure, and calcium and vitamin D for ...
(Date:12/16/2009)... 16 For wounded U.S. servicemen ... in Washington, D.C., the holidays can be a particularly ... travel home rely more than ever on the healing ... week, calling home just got easier for Walter Reed ... cards, which will provide hundreds of minutes of holiday ...
Breaking Medicine News(10 mins):Health News:Smart Balance Authorizes Stock Repurchase Program 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:Most Stem Cells Used in Research Come From Whites 2Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2
... of the American College of Gastroenterology suggests that illness ... with mothers who have Irritable Bowel Syndrome (IBS) may ... one-on-one contact with their mothers. ,Researcher ... Washington looked at survey data from 631 children of ...
... Doctors working in Iraq admit that more than half of ... equipment and more experienced staff and were available.// ... say that as the violence escalates, the reality is that ... figures from Iraqi authorities and UN agencies suggest that more ...
... help teenagers manage stress better than those who have ... ,Lisa Kiang and colleagues at the department of ... Chinese and Mexican backgrounds. They found that the ethnic ... daily psychological well-being, according to a release on the ...
... World Health Organization has reported that for every four ... are overweight, 30% of them clinically obese.// ... could one day cripple economies. WHO says that although ... but still constitutes a global epidemic. ,Statistics ...
... of carrot juice-linked botulism has been reported in Canada following ... carrot juice earlier// this month. ,According to reports ... while the first two are from Toronto. It is not ... affected products are produced in California and sold under the ...
... suspended flu vaccine administration on Sunday following the deaths ... media, the fourth death was reported later. , ... the vaccines,' said Inbal Jacobs, a ministry spokeswoman. According to ... few days were from a southern Israeli town of Kiryat ...
Other Medicine News:Health News:Gender and Family Size Influences IBS Symptoms in Children 2Health News:Scourge of Obesity 2
... restores the patients Quality of life by ... is not physically active. Cylos incorporates a ... restoration of hemodynamics in Atrial Fibrillation. Easy ... Home monitoring in combination with automatic functionality ...
The Victory single- and dual-chamber rate-responsive pacemakers from St. Jude Medical are advanced-feature systems, designed to save valuable clinic time, maximize patient safety, and provide other t...
... The Safe-Cross System facilitates ... intervention devices to cross ... The Safe-Cross system ... the Optical Coherence Reflectometry ...
... Infinix CS-i delivers on the promise ... empowering Cardiologists with outstanding image quality, ... free imaging of small devices and ... industry leading resolution at lower dose ...
Medicine Products: